Press Releases

---------------------------------------------------------------- FOR IMMEDIATE RELEASE

CONTACTS:	César García, Chairman and Chief Executive Officer
	818-709-1244
	-or-
	Ron Stabiner, The Wall Street Group, Inc.
	212-888-4848

IRIS EXPECTS TO MORE THAN TRIPLE REVENUES AND PROFITS IN CURRENT FIVE YEAR GROWTH PROGRAM, SHAREHOLDERS TOLD; FIRST FIVE YEAR PROGRAM WITNESSED 28% COMPOUND REVENUE GROWTH

CHATSWORTH, CA, June 13, 2008 - IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), "expects to more than triple revenues and profits in the new five year growth initiative instituted as of the beginning of this year," César García, Chairman, President and Chief Executive Officer told the Annual Meeting of Shareholders today.

"In the five years ended December 31, 2007 the Company achieved a 28% compound revenue growth and in that 20-quarter period invested $37 million in research and development while still exceeding comparable quarter revenues 18 times, comparable quarter profits and earnings per share 14 times and saw cash grow 12-fold to $28 million after two technology acquisitions. We expect to more than exceed that growth pattern as we go forward."

Mr. García noted that "in the first five year program we transformed a domestic company with a legacy urinalysis product into a world leader in this category, advancing our strategy of building recurring revenue from consumables and service. There are now more than 1,800 iQ^®200 Urine Microscopy analyzers in the field, and the number expands each month, each contributing to this corporate goal of high margin revenues. We have now expanded our horizon to incorporate hematology and molecular diagnostics, broadening to some $4 Billion the market opportunity for IRIS' current and new products and technologies as compared with the $300 million market that existed five years ago for the then state-of-the-art urinalysis equipment market.

"We believe we have the scientific, financial and human resources to produce a company that in five years will be much larger and more profitable than IRIS is today, and one that also will be a world leader in quality in each of its selected categories. We intend to not only introduce a range of what we believe are paradigm changing technologies, but our strategy calls for aligning ourselves through joint ventures and licensing with the most respected international names in these arenas."

"We are off to a good start in meeting this objective," Mr. García said, "with first quarter financial metrics at record levels for revenues, profits, earnings per share and cash, compared to the same quarter the year before. We expect this trend to continue and expand," he said. Shareholders attending the annual meeting and those voting by proxy re-elected all seven members of the Company's Board of Directors. In addition to Mr. García, they are: Richard H. Williams, a businessman, entrepreneur and consultant to emerging growth companies; Thomas H. Adams, Ph.D., the Company's Chief Technology Officer; Steven M. Besbeck, former President and Chief Executive Officer of Aspyra, Inc.; Stephen E. Wasserman, former Group Vice President - Diagnostic Systems Products of Olympus America Inc.; Richard G. Nadeau, Ph.D., founder and Chairman of Vistar Ventures, and Michael D. Matte, CFO of QuePasa Corporation (QPSA). Shareholders also ratified the selection of BDO Seidman, LLP, as the Company's independent accountant for the fiscal year ended Dec. 31, 2008.

ABOUT IRIS INTERNATIONAL, INC.
IRIS International a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. Our products leverage our strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for our technology have been in the urinalysis market and we are the leading worldwide provider of urine microscopy systems, with an installed based of over 1,800 systems in over 50 countries.

SAFE HARBOR PROVISION
This press release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, regulatory developments, new product introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following: identification of feasible new product initiatives, management of R&D efforts and the resulting successful development of new products and product platforms; obtaining regulatory approvals for new and enhanced products; acceptance by customers of the Company's products; integration of acquired businesses; substantial expansion of international sales; reliance on key suppliers; the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures; potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and competitive factors, including pricing pressures and the introduction by others of new products with similar or better functionality than our products. These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.